INSP

Inspire Medical Systems remains fundamentally strong despite severe reimbursement and coding disruptions, which the market has mispriced as permanent impairment. INSP's gross margin expanded to 86%, and operating cash flow reached $82.5M over nine months, even as revenue declined 7.9% year-over-year due to administrative headwinds. Management attributes nearly all revenue shortfall to coding issues, with growth expected to resume post-2027 as a permanent CPT code takes effect in January 2028.

MINNEAPOLIS, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Stifel 2026 Healthcare Conference on Tuesday, November 10, 2026. Inspire is scheduled to present at 2:40 p.m.

Inspire Medical Systems, Inc. ( INSP ) Q3 2026 Earnings Call November 2, 2026 5:00 PM EST Company Participants Timothy Herbert - Founder, Chairman, CEO & President Matthew Osberg - Executive VP & CFO Conference Call Participants Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Adam Maeder - Piper Sandler & Co., Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Anthony Petrone - Mizuho Securities USA LLC, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Richard Newitter - Truist Securities, Inc., Research Division Travis Steed - BofA Securities, Research Division Keith Hinton - Prime Executions, Inc., Research Division Suraj Kalia - Oppenheimer & Co. Inc., Research Division Michael Sarcone - Jefferies LLC, Research Division David Rescott - Robert W. Baird & Co. Incorporated, Research Division Brett Fishbin - KeyBanc Capital Markets Inc., Research Division Michael Kratky - Leerink Partners LLC, Research Division Daniel Markowitz - Evercore ISI Institutional Equities, Research Division Christopher Pasquale Presentation Operator Good afternoon.

Inspire Medical Systems NYSE: INSP reported third-quarter revenue of $206.7 million, down 7.9% from a year earlier but up 3% sequentially, as stronger-than-expected U.S. performance offset weaker international results. The company said coding and reimbursement challenges continued to weigh on results, though management expressed growing confidence that the disruption is easing.

MINNEAPOLIS, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the Company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended September 30, 2026.

Inspire Medical Systems gains 47.8% in three months as improved reimbursement clarity, an earnings beat, $30 million in annual savings and new CPT codes boost recovery prospects.

MINNEAPOLIS, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the third quarter 2026 after the close of trading on Monday, November 2. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

INSP gains new Category I CPT codes for Inspire V procedures, creating a dedicated coding framework effective Jan. 1, 2028.

MINNEAPOLIS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that the American Medical Association (AMA) CPT® Editorial Panel has approved the establishment of a new set of Current Procedural Terminology (CPT®) codes that accurately describe and include the Inspire V system. The new Category I codes are scheduled to take effect on January 1, 2028.

Inspire Medical is navigating a major product transition as clinical evidence, patient access efforts and reimbursement progress support growth prospects.